Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | AOC2 | O75106 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909336 | 0.85 | EPHX2 (0.39) | JAK2JAK3JAK1 | |
| SCHEMBL22030495 | 0.80 | NPC1 (0.41) | DPP4CYP3A4FAAH | |
| SCHEMBL26148281 | 0.79 | DPP4 (0.41) | DPP4CYP3A4JAK2FAAHJAK1 | |
| SCHEMBL22891660 | 0.78 | DPP4 (0.38) | DPP4CYP3A4JAK2FAAHJAK1 | |
| SCHEMBL22891648 | 0.76 | CYP3A4 (0.40) | DPP4CYP3A4FAAH | |
| SCHEMBL22030873 | 0.76 | CYP3A4 (0.41) | DPP4CYP3A4FAAH | |
| SCHEMBL22030876 | 0.76 | CYP3A4 (0.41) | DPP4CYP3A4FAAH | |
| SCHEMBL17281953 | 0.75 | JAK2 (0.39) | JAK2JAK3 | |
| SCHEMBL26148275 | 0.75 | MEN1 (0.43) | JAK2JAK1 | |
| SCHEMBL26148274 | 0.74 | DPP4 (0.41) | DPP4FAAHJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | DPP4 1158/4885CYP3A4 2930/4885JAK2 1/4885 |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | JAK1, JAK2, JAK3 | DPP4 1302/4885CYP3A4 380/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.